Main content

    Prostate Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Metastatic Prostate Cancer


    Active Trials

    Metastatic Prostate Cancer

    Title: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
    Description: This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with prostate cancer that has spread to other parts of the body
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects, 18 y/o and older, with metastatic adenocarcinoma of the prostate
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study NRG-BR001

    Title: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Description: This study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm])
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Janssen PCR3001

    Title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
    Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of metastatic prostate cancer
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study S1216

    Title: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
    Description: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and at intermediate-risk for recurrence
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0815

    Title: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
    Description: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0924

    Title: Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
    Description: This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Alliance A031201

    • updated December 2015

    Back to top